Research Topics
Genomes and Genes | Emmanuel ZornSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
CD4+CD25+ regulatory T cells in human hematopoietic cell transplantationEmmanuel Zorn
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, MA 02115, USA
Semin Cancer Biol 16:150-9. 2006..These potential strategies are discussed herein. Coming years will undoubtedly yield additional knowledge on how to use T(reg) subsets in vivo and successfully control and modulate immune responses in patients post-HCT...
Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantationEmmanuel Zorn
Division of Hematologic Malignancies, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
Biol Blood Marrow Transplant 15:382-8. 2009..This study suggests that administration of low-dose IL-2 combined with adoptive CD4(+) cellular therapy may provide a mechanism to expand Treg in vivo...- Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host diseaseEmmanuel Zorn
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 106:2903-11. 2005..These findings support the development of new strategies to increase the number of Tregs following allogeneic hematopoietic stem cell transplantation to prevent or correct cGVHD... - Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosisRoberto Bellucci
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 109:2001-7. 2007..Interestingly, the epitope specificity of these PDC-E2 autoantibodies was distinctive, suggesting that the mechanisms leading to loss of tolerance in the transplantation patients are distinct from PBC... - IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivoEmmanuel Zorn
Division of Hematologic Malignancies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 108:1571-9. 2006..Our findings support the clinical evaluation of low-dose IL-2 to selectively modulate CD4+CD25+ Tregs and increase expression of FOXP3 in vivo... - Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptorRoberto Bellucci
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, M530, Boston, MA 02115, USA
Blood 105:3945-50. 2005..These results demonstrate that BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo... - Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remissionDavid B Miklos
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, M530, Boston, MA 02115, USA
Blood 105:2973-8. 2005..Antibody response to Y-chromosome encoded histocompatibility antigens (H-Y antigens) was also associated with maintenance of disease remission (P < .0001). B cells may provide a new target for immune intervention in chronic GVHD... - Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantationEmmanuel Zorn
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, M530, Boston, MA 02115, USA
J Exp Med 199:1133-42. 2004..The specificity for recipient male cells was mediated by the B cell response and not by donor T cells. This dual DBX/DBY antigen is the first mHA to be identified in the context of chronic GVHD... - Studying human regulatory T cells in vivoEmmanuel Zorn
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Cancer Res 12:5265-7. 2006 - Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group ReportKirk R Schultz
British Columbia Children s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
Biol Blood Marrow Transplant 12:126-37. 2006..Both approaches have merit and should be pursued. The consistent treatment and standardized documentation needed to support biomarker studies are most likely to be satisfied in prospective clinical trials... - Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donorsDavid B Miklos
Department of Medical Oncology and Biostatistical Science, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115
Blood 103:353-9. 2004..These studies demonstrate that the immune response to mHA includes the generation of specific antibodies and suggests that the serologic response to these antigens may also be useful in the identification of new mHAs... - Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cellsEmmanuel Zorn
Center for Hematologic Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Cancer Res 8:2052-60. 2002..It was not detected before DLI. CONCLUSIONS: These results indicate that CD4+ DLI elicits a potent allogeneic response mediated by mHA-specific CD8+ T cells...